173 related articles for article (PubMed ID: 37503332)
1. Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models.
Lotti R; Hundt JE; Ludwig RJ; Hammers CM; Bennett B; Amato A; Marconi A; Pincelli C
Front Immunol; 2023; 14():1193032. PubMed ID: 37503332
[TBL] [Abstract][Full Text] [Related]
2. Soluble Fas Ligand Is Essential for Blister Formation in Pemphigus.
Lotti R; Shu E; Petrachi T; Marconi A; Palazzo E; Quadri M; Lin A; O'Reilly LA; Pincelli C
Front Immunol; 2018; 9():370. PubMed ID: 29535737
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum: Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models.
Lotti R; Hundt JE; Ludwig RJ; Hammers CM; Bennett B; Amato A; Marconi A; Pincelli C
Front Immunol; 2024; 15():1331003. PubMed ID: 38322255
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic pathways in the pathogenesis of pemphigus: targets for new therapies.
Lotti R; Marconi A; Pincelli C
Curr Pharm Biotechnol; 2012 Aug; 13(10):1877-81. PubMed ID: 22250711
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice.
Amagai M; Nishikawa T; Nousari HC; Anhalt GJ; Hashimoto T
J Clin Invest; 1998 Aug; 102(4):775-82. PubMed ID: 9710446
[TBL] [Abstract][Full Text] [Related]
6. Two cases of cutaneous-type pemphigus vulgaris and a case of pemphigus foliaceus without mucosal involvement despite high anti-desmoglein 3 autoantibody levels.
Terada A; Akasaka E; Nakano H; Sawamura D
J Dermatol; 2023 Nov; 50(11):1501-1505. PubMed ID: 37485682
[TBL] [Abstract][Full Text] [Related]
7. Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice.
Hofrichter M; Dworschak J; Emtenani S; Langenhan J; Weiß F; Komorowski L; Zillikens D; Stöcker W; Probst C; Schmidt E; Goletz S
Front Immunol; 2018; 9():1935. PubMed ID: 30233569
[TBL] [Abstract][Full Text] [Related]
8. Pemphigus vulgaris: recent advances in our understanding of its pathogenesis.
Femiano F
Minerva Stomatol; 2007 Apr; 56(4):215-23. PubMed ID: 17452959
[TBL] [Abstract][Full Text] [Related]
9. In Vitro, Ex Vivo, and In Vivo Models for the Study of Pemphigus.
Lotti R; Atene CG; Zanfi ED; Bertesi M; Zanocco-Marani T
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806044
[TBL] [Abstract][Full Text] [Related]
10. IgG against the Membrane-Proximal Portion of the Desmoglein 3 Ectodomain Induces Loss of Keratinocyte Adhesion, a Hallmark in Pemphigus Vulgaris.
Hudemann C; Exner Y; Pollmann R; Schneider K; Zakrzewicz A; Feldhoff S; Schmidt T; Spindler V; Rafei-Shamsabadi D; Völlner F; Waschke J; Tikkanen R; Hertl M; Eming R
J Invest Dermatol; 2023 Feb; 143(2):254-263.e3. PubMed ID: 36089007
[TBL] [Abstract][Full Text] [Related]
11. The human skin organ culture model as an optimal complementary tool for murine pemphigus models.
Hartmann V; Hariton WV; Rahimi S; Hammers CM; Ludwig RJ; Müller EJ; Hundt JE
Lab Anim; 2023 Aug; 57(4):381-395. PubMed ID: 36647613
[TBL] [Abstract][Full Text] [Related]
12. Pemphigus, a pathomechanism of acantholysis.
Furue M; Kadono T
Australas J Dermatol; 2017 Aug; 58(3):171-173. PubMed ID: 28211055
[TBL] [Abstract][Full Text] [Related]
13. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions.
Nguyen VT; Ndoye A; Shultz LD; Pittelkow MR; Grando SA
J Clin Invest; 2000 Dec; 106(12):1467-79. PubMed ID: 11120754
[TBL] [Abstract][Full Text] [Related]
14. Ca
Schmitt T; Egu DT; Walter E; Sigmund AM; Eichkorn R; Yazdi A; Schmidt E; Sárdy M; Eming R; Goebeler M; Waschke J
Br J Dermatol; 2021 Sep; 185(3):595-604. PubMed ID: 33792909
[TBL] [Abstract][Full Text] [Related]
15. Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering.
Yoshida K; Ishii K; Shimizu A; Yokouchi M; Amagai M; Shiraishi K; Shirakata Y; Stanley JR; Ishiko A
J Dermatol Sci; 2017 Mar; 85(3):197-207. PubMed ID: 28024684
[TBL] [Abstract][Full Text] [Related]
16. The involvement of ADAM10 in acantholysis in mucocutaneous pemphigus vulgaris depends on the autoantibody profile of each patient.
Ivars M; España A; Alzuguren P; Pelacho B; Lasarte JJ; López-Zabalza MJ
Br J Dermatol; 2020 May; 182(5):1194-1204. PubMed ID: 31370093
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic mechanism in pemphigus autoimmunoglobulins-induced acantholysis--possible involvement of the EGF receptor.
Frusić-Zlotkin M; Raichenberg D; Wang X; David M; Michel B; Milner Y
Autoimmunity; 2006 Nov; 39(7):563-75. PubMed ID: 17101500
[TBL] [Abstract][Full Text] [Related]
18. A Novel In Vivo Active Pemphigus Model Targeting Desmoglein1 and Desmoglein3: A Tool Representing All Pemphigus Variants.
Lotti R; Atene CG; Zanfi ED; Bertesi M; Pincelli C; Zanocco-Marani T
Biology (Basel); 2023 May; 12(5):. PubMed ID: 37237515
[No Abstract] [Full Text] [Related]
19. What protein kinases are crucial for acantholysis and blister formation in pemphigus vulgaris? A systematic review.
Brescacin A; Baig Z; Bhinder J; Lin S; Brar L; Cirillo N
J Cell Physiol; 2022 Jul; 237(7):2825-2837. PubMed ID: 35616233
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel therapeutic targets for blocking acantholysis in pemphigus.
Burmester IAK; Flaswinkel S; Thies CS; Kasprick A; Kamaguchi M; Bumiller-Bini V; Emtenani S; Feldmann N; Kridin K; Schmidt E; van Beek N; Zillikens D; Hammers CM; Hundt JE; Ludwig RJ
Br J Pharmacol; 2020 Nov; 177(22):5114-5130. PubMed ID: 32815159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
